Molecular characterization of drug-resistant and -susceptible Mycobacterium tuberculosis isolated from patients with tuberculosis in Korea

Diagnostic Microbiology and Infectious Disease

Volumn 72, Issue 1, 2012, Pages 52-61

  Yoon, Jee Hyun ^a   Nam, Ji Sun ^a   Kim, Kyung Jin ^a   Choi, Yeonim ^b   Lee, Hyeyoung ^b   Cho, Sang Nae ^a   Ro, Young Tae ^a  

^a Konkuk University School of Medicine   (South Korea)

^b Yonsei University Wonju   (South Korea)

Author keywords

Drug resistant; Korea; Mutation analysis; Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; EMBB GENE; GENE MUTATION; GENE SEQUENCE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INHA GENE; KATG GENE; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RPOB GENE; SOUTH KOREA;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CATALASE; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, BACTERIAL; HUMANS; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; POINT MUTATION; PROMOTER REGIONS, GENETIC; REPUBLIC OF KOREA; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 83055186499     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.09.010     Document Type: Article

References (53)

1. Abe C., Kobayashi I., Mitarai S., Wada M., Kawabe Y., Takashima T., Suzuki K., Sng L.H., Wang S., Htay H.H., Ogata H. Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan. J. Clin. Microbiol. 2008, 46:2263-2268.
2. Ahmad S., Jaber A.A., Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis 2007, 87:123-129.
3. Bai G.H., Park Y.K., Choi Y.W., Bai J.I., Kim H.J., Chang C.L., Lee J.K., Kim S.J. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int. J. Tuberc. Lung. Dis. 2007, 11:571-576.
4. Bolotin S., Alexander D.C., Chedore P., Drews S.J., Jamieson F. Molecular characterization of drug-resistant Mycobacterium tuberculosis isolates from Ontario, Canada. J. Antimicrob. Chemother. 2009, 64:263-266.
5. Brewer T.F., Heymann S.J. Long time due: reducing tuberculosis mortality in the 21st century. Arch. Med. Res. 2005, 36:617-621.
6. Campbell P.J., Morlock G.P., Sikes R.D., Dalton T.L., Metchock B., Starks A.M., Hooks D.P., Cowan L.S., Plikaytis B.B., Posey J.E. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob. Agents. Chemother. 2011, 55:2032-2041.
7. Cho E.H., Bae H.K., Kang S.K., Lee E.H. Detection of isoniazid and rifampicin resistance by sequencing of katG, inhA, and rpoB genes in Korea. Korean J. Lab. Med. 2009, 29:455-460.
8. Choi J.H., Lee K.W., Kang H.R., Hwang Y.I., Jang S., Kim D.G., Kim C.H., Hyun I.G., Shin T.R., Park S.M., Lee M.G., Lee C.Y., Park Y.B., Jung K.S. Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. Chest 2010, 137:393-400.
9. Davies A.P., Billington O.J., McHugh T.D., Mitchison D.A., Gillespie S.H. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. J. Clin. Microbiol. 2000, 38:3686-3688.
10. Espinal M.A., Laszlo A., Simonsen L., Boulahbal F., Kim S.J., Reniero A., Hoffner S., Rieder H.L., Binkin N., Dye C., Williams R., Raviglione M.C. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N. Engl. J. Med. 2001, 344:1294-1303.
11. Gagneux S., Burgos M.V., DeRiemer K., Encisco A., Mu;oz S., Hopewell P.C., Small P.M., Pym A.S. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS. Pathog. 2006, 2:e61.
12. Guo H., Seet Q., Denkin S., Parsons L., Zhang Y. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J. Med. Microbiol. 2006, 55:1527-1531.
13. Hazbn M.H., Bobadilla del Valle M., Guerrero M.I., Varma-Basil M., Filliol I., Cavatore M., Colangeli R., Safi H., Billman-Jacobe H., Lavender C., Fyfe J., Garca-Garca L., Davidow A., Brimacombe M., Len C.I., Porras T., Bose M., Chaves F., Eisenach K.D., Sifuentes-Osornio J., Ponce de Len A., Cave M.D., Alland D. Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance. Antimicrob. Agents Chemother. 2005, 49:3794-3802.
14. Herrera-Len L., Molina T., Saz P., Sez-Nieto J.A., Jimnez M.S. New multiplex PCR for rapid detection of isoniazid-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 2005, 49:144-147.
15. Hillemann D., Kubica T., Agzamova R., Venera B., Rsch-Gerdes S., Niemann S. Rifampicin and isoniazid resistance mutations in Mycobacterium tuberculosis strains isolated from patients in Kazakhstan. Int. J. Tuberc. Lung Dis. 2005, 9:1161-1167.
16. Hirano K., Takahashi M., Kazumi Y., Fukasawa Y., Abe C. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber. Lung Dis. 1997, 78:117-122.
17. Hfling C.C., Pavan E.M., Giampaglia C.M., Ferrazoli L., Aily D.C., de Albuquerque D.M., Ramos M.C. Prevalence of katG Ser315 substitution and rpoB mutations in isoniazid-resistant Mycobacterium tuberculosis isolates from Brazil. Int. J. Tuberc. Lung Dis. 2005, 9:87-93.
18. Hu Y., Hoffner S., Jiang W., Wang W., Xu B. Genetic characterisation of drug-resistant Mycobacterium tuberculosis in rural China: a population-based study. Int. J. Tuberc. Lung. Dis. 2010, 14:210-216.
19. Kim S.J., Bai G.H., Hong Y.P. Drug-resistant tuberculosis in Korea, 1994. Int. J. Tuberc. Lung Dis. 1997, 1:302-308.
20. Kim S.Y., Park Y.J., Song E., Jang H., Kim C., Yoo J., Kang S.J. Evaluation of the CombiChip Mycobacteria Drug-Resistance Detection DNA chip for identifying mutations associated with resistance to isoniazid and rifampin in Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis. 2006, 54:203-210.
21. Lee A.S., Othman S.N., Ho Y.M., Wong S.Y. Novel mutations within the embB gene in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents. Chemother. 2004, 48:4447-4449.
22. Lee A.S., Teo A.S., Wong S.Y. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 2001, 45:2157-2159.
23. Lee K.W., Lee J.M., Jung K.S. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. J. Korean Med. Sci. 2001, 16:537-543.
24. Luo T., Zhao M., Li X., Xu P., Gui X., Pickerill S., DeRiemer K., Mei J., Gao Q. Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China. Antimicrob. Agents Chemother. 2010, 54:1075-1081.
25. Mestdagh M., Fonteyne P.A., Realini L., Rossau R., Jannes G., Mijs W., De Smet K.A., Portaels F., Van den Eeckhout E. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1999, 43:2317-2319.
26. Miller L.P., Crawford J.T., Shinnick T.M. The rpoB gene of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1994, 38:805-811.
27. Mokrousov I., Otten T., Vyshnevskiy B., Narvskaya O. Detection of embB306 mutations in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis from northwestern Russia: implications for genotypic resistance testing. J. Clin. Microbiol. 2002, 40:3810-3813.
28. Morlock G.P., Crawford J.T., Butler W.R., Brim S.E., Sikes D., Mazurek G.H., Woodley C.L., Cooksey R.C. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2000, 44:2291-2295.
29. Murray M.G., Thompson W.F. Rapid isolation of high molecular weight plant DNA. Nucleic. Acids Res. 1980, 8:4321-4325.
30. Musser J.M. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin. Microbiol. Rev. 1995, 8:496-514.
31. Nam Y.H., Lee S.H., Ahn Y.C., Cho M.H., Jang W.C., Park S.M., Kwon P.S., Kim J.W. Detection of rifampin resistant Mycobacterium tuberculosis complex using denaturing HPLC. Korean J. Lab. Med. 2008, 28:95-102.
32. O'Sullivan D.M., McHugh T.D., Gillespie S.H. Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution?. J. Antimicrob. Chemother. 2005, 55:674-679.
33. Park Y.K., Shin S., Ryu S., Cho S.N., Koh W.J., Kwon O.J., Shim Y.S., Lew W.J., Bai G.H. Comparison of drug resistance genotypes between Beijing and non-Beijing family strains of Mycobacterium tuberculosis in Korea. J. Microbiol. Methods 2005, 63:165-172.
34. Plinke C., Rsch-Gerdes S., Niemann S. Significance of mutations in embB codon 306 for prediction of ethambutol resistance in clinical Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 2006, 50:1900-1902.
35. Ramaswamy S., Musser J.M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 1998, 79:3-29.
36. Safi H., Sayers B., Hazbn M.H., Alland D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob. Agents Chemother. 2008, 52:2027-2034.
37. Sajduda A., Brzostek A., Poplawska M., Augustynowicz-Kopec E., Zwolska Z., Niemann S., Dziadek J., Hillemann D. Molecular characterization of rifampin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Poland. J. Clin. Microbiol. 2004, 42:2425-2431.
38. Sandgren A., Strong M., Muthukrishnan P., Weiner B.K., Church G.M., Murray M.B. Tuberculosis drug resistance mutation database. PLoS. Med. 2009, 6:e2.
39. Scorpio A., Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 1996, 2:662-667.
40. Sekiguchi J., Miyoshi-Akiyama T., Augustynowicz-Kopeć E., Zwolska Z., Kirikae F., Toyota E., Kobayashi I., Morita K., Kudo K., Kato S., Kuratsuji T., Mori T., Kirikae T. Detection of multidrug resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 2007, 45:179-192.
41. Shen X., Shen G.M., Wu J., Gui X.H., Li X., Mei J., DeRiemer K., Gao Q. Association between embB codon 306 mutations and drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents. Chemother. 2007, 51:2618-2620.
42. Singh P., Wesley C., Jadaun G.P., Malonia S.K., Das R., Upadhyay P., Faujdar J., Sharma P., Gupta P., Mishra A.K., Singh K., Chauhan D.S., Sharma V.D., Gupta U.D., Venkatesan K., Katoch V.M. Comparative evaluation of Lwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 2007, 45:76-80.
43. Somoskovi A., Parsons L.M., Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir. Res. 2001, 2:164-168.
44. Starks A.M., Gumusboga A., Plikaytis B.B., Shinnick T.M., Posey J.E. Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2009, 53:1061-1066.
45. Stottmeier K.D., Beam R.E., Kubica G.P. Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar. Am. Rev. Respir. Dis. 1967, 96:1072-1075.
46. Suzuki Y., Suzuki A., Tamaru A., Katsukawa C., Oda H. Rapid detection of pyrazinamide-resistant Mycobacterium tuberculosis by a PCR-based in vitro system. J. Clin. Microbiol. 2002, 40:501-507.
47. Telenti A., Imboden P., Marchesi F., Lowrie D., Cole S., Colston M.J., Matter L., Schopfer K., Bodmer T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993, 341:647-650.
48. Telenti A., Philipp W.J., Sreevatsan S., Bernasconi C., Stockbauer K.E., Wieles B., Musser J.M., Jacobs W.R. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat. Med. 1997, 3:567-570.
49. Trivedi S.S., Desai S.G. Pyrazinamidase activity of Mycobacterium tuberculosis-a test of sensitivity to pyrazinamide. Tubercle 1987, 68:221-224.
50. Van Deun A., Barrera L., Bastian I., Fattorini L., Hoffmann H., Kam K.M., Rigouts L., Rsch-Gerdes S., Wright A. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J. Clin. Microbiol. 2009, 47:3501-3506.
51. Wayne L.G. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am. Rev. Respir. Dis. 1974, 109:147-151.
52. Zenteno-Cuevas R., Zenteno J.C., Cuellar A., Cuevas B., Sampieri C.L., Riviera J.E., Parissi A. Mutations in rpoB and katG genes in Mycobacterium isolates from the Southeast of Mexico. Mem. Inst. Oswaldo Cruz. 2009, 104:468-472.
53. Zhang Y., Mitchison D. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 2003, 7:6-21.